Seattle Genetics Announces Vadastuximab Talirine Phase 1 Clinical Data Featured in Press Program and Oral Presentation Demonstrate 41% Complete Remission Rate, in Newly Diagnosed AML Patients Treated with 3A Combination Therapy
Charles Gross